Nisa Investment Advisors LLC Cuts Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Nisa Investment Advisors LLC lowered its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 6.9% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 408,793 shares of the biopharmaceutical company's stock after selling 30,223 shares during the quarter. Nisa Investment Advisors LLC's holdings in Gilead Sciences were worth $37,760,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. nVerses Capital LLC acquired a new stake in shares of Gilead Sciences in the third quarter valued at about $25,000. Decker Retirement Planning Inc. acquired a new stake in Gilead Sciences in the fourth quarter valued at approximately $29,000. Valued Wealth Advisors LLC raised its stake in shares of Gilead Sciences by 101.9% during the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 161 shares during the period. Strategic Investment Solutions Inc. IL acquired a new position in shares of Gilead Sciences during the second quarter worth $33,000. Finally, Friedenthal Financial purchased a new position in shares of Gilead Sciences in the third quarter valued at $50,000. Institutional investors and hedge funds own 83.67% of the company's stock.

Gilead Sciences Price Performance

NASDAQ GILD opened at $92.96 on Wednesday. The company has a 50-day moving average price of $91.65 and a two-hundred day moving average price of $84.38. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $98.90. The stock has a market cap of $115.85 billion, a price-to-earnings ratio of 1,032.89, a price-to-earnings-growth ratio of 1.29 and a beta of 0.18. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.58 by $0.44. The business had revenue of $7.55 billion during the quarter, compared to analyst estimates of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business's revenue for the quarter was up 7.0% compared to the same quarter last year. During the same period in the prior year, the company posted $2.29 EPS. Analysts forecast that Gilead Sciences, Inc. will post 4.36 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, December 30th. Investors of record on Friday, December 13th were paid a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.31%. The ex-dividend date of this dividend was Friday, December 13th. Gilead Sciences's dividend payout ratio is currently 3,422.22%.

Insider Activity at Gilead Sciences

In other news, insider Merdad Parsey sold 164,211 shares of Gilead Sciences stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the transaction, the insider now directly owns 80,801 shares in the company, valued at approximately $7,427,227.92. This trade represents a 67.02 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of the company's stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total value of $228,375.00. Following the completion of the sale, the chief financial officer now owns 129,873 shares of the company's stock, valued at approximately $11,863,898.55. This trade represents a 1.89 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 456,234 shares of company stock worth $42,130,461 over the last ninety days. 0.29% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on GILD shares. BMO Capital Markets lifted their price target on shares of Gilead Sciences from $94.00 to $102.00 and gave the stock an "outperform" rating in a research note on Thursday, November 7th. Leerink Partners upgraded Gilead Sciences from a "market perform" rating to an "outperform" rating and boosted their price target for the stock from $74.00 to $96.00 in a research note on Monday, October 21st. JPMorgan Chase & Co. raised their price objective on Gilead Sciences from $100.00 to $105.00 and gave the company an "overweight" rating in a research note on Thursday, November 7th. Barclays upped their target price on Gilead Sciences from $84.00 to $95.00 and gave the company an "equal weight" rating in a research report on Thursday, November 7th. Finally, Truist Financial lifted their price target on shares of Gilead Sciences from $83.00 to $97.00 and gave the stock a "hold" rating in a research note on Friday, November 8th. Eleven research analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have issued a strong buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $97.96.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.